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Abstract
Background: Based on their different mechanisms of action, non-overlapping side effects and radiosensitising
potential, combining the antimetabolites pemetrexed (multitargeted antifolate, MTA) and gemcitabine (2′,2′-
difluorodeoxycytidine, dFdC) with irradiation (RT) seems promising. This in vitro study, for the first time, presents
the triple combination of MTA, dFdC and irradiation using various treatment schedules.
Methods: The cytotoxicity, radiosensitising potential and cell cycle effect of MTA were investigated in A549
(NSCLC) and CAL-27 (SCCHN) cells. Using simultaneous or sequential exposure schedules, the cytotoxicity and
radiosensitising effect of 24 h MTA combined with 1 h or 24 h dFdC were analysed.
Results: Including a time interval between MTA exposure and irradiation seemed favourable to MTA immediately
preceding or following radiotherapy. MTA induced a significant S phase accumulation that persisted for more than
8 h after drug removal. Among different MTA/dFdC combinations tested, the highest synergistic interaction was
produced by 24 h MTA followed by 1 h dFdC. Combined with irradiation, this schedule showed a clear
radiosensitising effect.
Conclusions: Results from our in vitro model suggest that the sequence 24 h MTA ® 1 h dFdC ® RT is the most
rational design and would, after confirmation in an in vivo setting, possibly provide the greatest benefit in the
clinic.
Background
During the past decades, the use of chemotherapeutic
drugs in combination with radiotherapy has become a
common strategy for the treatment of different solid
tumours, improving cancer care dramatically. Combin-
ing chemotherapy and radiotherapy has a solid and
appealing biologic rationale. Firstly, whereas radiother-
apy is aimed at controlling the primary tumour, the
cytotoxic drug also eradicates distant micrometastases, a
scenario defined as spatial cooperation. Secondly,
chemotherapy can possibly enhance the effects of ionis-
ing radiation, a process called radiosensitisation [1].
The availability of several new active compounds has
led to the development of promising new combinations.
Many of those chemoradiotherapy combinations include
antimetabolites, because of their efficacy, their generally
well-defined mechanisms of action and mostly manage-
able toxicities [2]. In this in vitro study, we describe for
the first time the triple combination of the antimetabo-
lites gemcitabine and pemetrexed with irradiation in
two human tumour cell lines.
Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a
synthetic pyrimidine nucleoside analogue clinically
active against a wide variety of solid tumours. Transport
of gemcitabine across the plasma membrane is mostly
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porter 1 (hENT1) [3]. Intracellularly, the prodrug gemci-
tabine requires phosphorylation and hence activation by
deoxycytidine kinase (dCK). The diphosphate (dFdCDP)
and triphosphate (dFdCTP) forms of the drug are pre-
sumed to be responsible for the cytotoxic effect, as they
inhibit ribonucleotide reductase or are incorporated into
the DNA, leading to chain termination, respectively [4].
In addition to its cytotoxic effect, gemcitabine has
potent radiosensitising properties, as shown in both pre-
clinical and clinical settings [5]. The current evidence
suggests that accumulation in the S phase of the cell
cycle, depletion of dATP pools, reduction of apoptotic
threshold, inhibition of DNA synthesis and reduction of
DNA repair might contribute to, or might even be
essential for gemcitabine-mediated radiosensitisation
[6-10]. Recently, Pauwels et al could grant a role for cell
cycle perturbations and activation of the extrinsic apop-
totic pathway in the radiosensitising effect of gemcita-
bine [10]. On the other hand, it has been suggested that
radiosensitisation by gemcitabine may be primarily
explained by the significant inhibition of DNA repair
following combined radiation and gemcitabine treat-
ment. DNA repair pathways using short DNA patches,
such as non-homologous end joining and base excision
repair, are thought not to play an important role in
gemcitabine-mediated radiosensitisation [9,11]. Instead,
homologous recombination, a long-patch DNA repair
pathway, has been argued to be the target for gemcita-
bine to enhance cellular radiosensitivity [9]. Moreover,
the role of the mismatch repair (MMR) system, an inter-
mediate-patch DNA repair pathway, may be of relevance
[12]. A dramatic increase of nucleotide misincorpora-
tions in gemcitabine-treated (MMR deficient) cells was
demonstrated, presumably due to dNTP pool imbal-
ances (particularly dATP depletion) [8,13]. Van Bree et
al showed that MMR proficiency reduced radiosensitisa-
tion after 24 h incubation with a low dose of gemcita-
bine, suggesting that the MMR status might affect the
recovery from gemcitabine treatment [14].
Pemetrexed (multitargeted antifolate, MTA) is a new-
generation antimetabolite with antitumour activity
against a broad range of human malignancies [15]. It
was approved by the FDA for first-line treatment of
inoperable malignant mesothelioma in combination with
cisplatin [16]. Successively, pemetrexed was also investi-
gated in non-small cell lung cancer (NSCLC), where it
was FDA-approved as second-line therapy in patients
with previously chemotherapy-treated advanced NSCLC
[17], as first-line therapy, in combination with cisplatin,
for chemotherapy-naive NSCLC patients [18], and, very
recently, for maintenance treatment of patients with
locally advanced or metastatic non-squamous NSCLC
whose disease had not progressed after four cycles of
platinum-based first-line chemotherapy [19].
Pemetrexed acts as a multitargeted antifolate by inhi-
biting multiple key enzymes involved in both pyrimidine
and purine synthesis, its primary targets being thymidy-
late synthase (TS), dihydrofolate reductase (DHFR) and
glycinamide ribonucleotide formaldehyde transferase
(GARFT). Pemetrexed enters the cell mainly by a
reduced folate carrier system. Once inside the cell,
pemetrexed is an excellent s u b s t r a t ef o rt h ee n z y m e
folylpolyglutamate synthase (FPGS) [20], which rapidly
converts pemetrexed to its active polyglutamate deriva-
tives that have a substantially higher potency for inhibi-
tion of TS and GARFT [21]. It is believed that
polyglutamation of pemetrexed plays a profound role in
determining both the selectivity and the antitumour
activity of this agent.
The ability of pemetrexed to deplete cellular nucleo-
tide pools, to modulate the cell cycle, and to induce
apoptosis makes this drug an attractive cytotoxic agent
for polychemotherapy regimens and combination with
radiotherapy [22]. In preclinical studies, radiosensitisa-
tion by pemetrexed was observed in human colon,
breast, cervix and lung carcinoma cells [23]. In vivo,
combination of pemetrexed with fractionated radiother-
apy produced additive to greater than additive antitu-
mour activity in murine and human tumour xenografts
[24,25]. In a phase I study, it was suggested that peme-
trexed could be administered at systemically active
doses in combination with radiotherapy [26]. These
findings prompted further investigation of the radiosen-
sitising effect of pemetrexed.
The aim of the present study is the exploration of the
cytotoxic (and not toxic) effects of combinations of
pemetrexed and gemcitabine alone or combined with
irradiation using various treatment schedules in two
human carcinoma cell lines. Given the three approved
indications for pemetrexed in the treatment of NSCLC,
we selected the A549 NSCLC cell line. As radiotherapy
in combination with gemcitabine is reported to be feasi-
ble and highly active in the treatment of locally
advanced squamous cell carcinoma of the head and
neck (SCCHN) [27], we also included the CAL-27
SCCHN cell line.
Methods
Cell lines
The cell lines used in this study were CAL-27 (squa-
mous cell carcinoma of the tongue) and A549 (lung ade-
nocarcinoma). A549 was cultured in RPMI-1640
medium, supplemented with 10% dialysed foetal calf
serum, 2 mM glutamine and 1 mM sodium pyruvate.
CAL-27 was cultured in DMEM medium, supplemented
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mine (Invitrogen, Merelbeke, Belgium). No antibiotics
were used. Cells were grown as monolayers and cultures
were maintained in exponential growth in a humidified
5% CO2/95% air atmosphere at 37°C. For subsequent
experiments, cells were collected by trypsinisation,
counted, and plated as specified below. The cell dou-
bling times of A549 and CAL-27 cells in our experimen-
tal conditions were 28 h and 33 h, respectively.
Cytotoxicity experiments
Cells were plated in 48 well plates and seeding densities
were 500 cells/cm
2 for A549 and 1400 cells/cm
2 for
CAL-27, assuring exponential growth. Cells were incu-
bated with pemetrexed alone (0-2000 nM for 24 h),
gemcitabine alone (0-100 nM for 24 h or 0-5 μMf o r
1 h) or with a combination of both, where one drug was
used at a fixed concentration, while a concentration
range of the other drug was added. Three combination
schedules were tested: (1) simultaneous exposure to
pemetrexed and gemcitabine for 24 h; (2) gemcitabine
for 1 h or 24 h immediately followed by pemetrexed for
24 h; (3) pemetrexed for 24 h immediately followed by
gemcitabine for 1 h or 24 h. Cell survival was deter-
mined by the sulforhodamine B (SRB) assay, as pre-
viously described [28]. The experimental conditions
adopted in this study, including time of exposure to
gemcitabine and pemetrexed, are similar to those
selected in previous studies [10,22,29,30]. In simulta-
neous experiments, treatment exposure time was 24 h.
To reduce the variation in drug efficacy associated with
time of drug addition relative to plating time, the
sequential schemes examined the effect of both a 1-h
and a 24-h gemcitabine exposure on the cytotoxicity of
pemetrexed. Since several clinical studies have indicated
that administration of gemcitabine and pemetrexed
immediately after each other is well tolerated and clini-
cally active [31-33], no wash out with drug-free medium
was included in the sequential treatment schedules.
Chemoradiation experiments
Cells were plated in 48 well plates, with plating densities
assuring exponential growth during the experiments.
The radiosensitising effect of pemetrexed alone was
investigated by including different time intervals (24 h,
8 h, 4 h, 1 h, 0 h) between 24 h pemetrexed treatment
and irradiation (0-8 Gy, room temperature, linear accel-
erator (URA, Antwerp)). The same time intervals as in a
previous study investigating the schedule-dependency of
gemcitabine treatment combined with radiation were
included [34]. In additional experiments, cells were first
irradiated, immediately followed by 24 h incubation with
pemetrexed. The triple interaction between pemetrexed,
gemcitabine and irradiation was investigated including
the three combination schedules previously mentioned,
immediately followed by irradiation.
After 7 or 8 days, survival was determined by the SRB
assay. For in vitro radiosensitivity testing, this method
was comparable to the clonogenic assay, taking into
account some critical aspects [28].
Cell cycle experiments
Cells were plated in 6-well plates and incubated with
50 nM (CAL-27) or 100 nM (A549) pemetrexed for 24
h. Cell cycle analysis was performed 0, 1, 4, 8 or 24 h
after drug wash out (referred to as 24+0, 24+1, 24+4,
24+8 and 24+24 respectively). Hence, cells were treated
with pemetrexed using the same treatment schedules as
adopted in the pemetrexed-radiotherapy experiments,
but without subsequent radiation. As such, cell cycle
perturbations at the time of irradiation were measured.
Cell cycle distribution was monitored according to the
Vindelov method, as described previously [34]. Samples
were analysed using a FACScan flow cytometer (Becton
Dickinson). Histograms of DNA content were analysed
using FlowJo software to determine the fractions in each
phase of the cell cycle (G0/G1,Sa n dG 2/M). The Wat-
son-Pragmatic model was used to fit curves to the stages
of the cell cycle [35].
Statistical analysis
All experiments were performed at least three times.
The results are presented as mean ± SD. Possible signifi-
cant differences (p < 0.05) were evaluated with two-sam-
ple t-tests and two-way ANOVA, using SPSS v16.0
software.
Survival rates were calculated by: [mean optical den-
sity (OD) of treated cells/mean OD of control cells] ×
100%. Radiation dose-survival curves were fitted accord-
ing to the linear-quadratic model using WinNonlin soft-
ware (Pharsight, Mountain View, USA) with survival =
exp(-aD-bD
2). The radiation dose-survival curves were
corrected for the cytotoxic effect of the drugs alone.
The following parameters were calculated: IC50 (drug
concentration causing 50% growth inhibition); ID50
(radiation dose causing 50% growth inhibition); SF2 (sur-
viving fraction at 2 Gy); and MID (mean inactivation
dose, calculated by numeric integration of the linear-
quadratic curve [36]). The radiosensitising effect was
represented by the dose enhancement factor (DEF), cal-
culated as the ID50 for control, untreated cells divided
by the ID50 for the treated cells.
The interaction between pemetrexed, gemcitabine
and/or radiation was analysed using CalcuSyn software
(Biosoft, Cambridge, UK) to determine possible syner-
gism. Data from the cell survival curves were expressed
as the fraction of cells killed by the individual drugs or
the combination in drug-treated cells compared with
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the Chou-Talalay method, which calculates the combi-
nation index (CI). The analysis is performed based on
the following equation: CI = (D)1/(Dx)1 +( D ) 2/(Dx)2
where (D)1 and (D)2 are the doses (or concentrations) of
drug 1 and drug 2 that have x% effect when used in
combination and (Dx)1 and (Dx)2 are the doses of drug
1 and drug 2 that have the same x% effect (i.e. isoeffect)
when used alone. (Dx)1 and (Dx)2 can be readily calcu-
lated from the median-effect equation of Chou: Dx =
Dm [fa /(1-fa)]
1/m, where fa is the fraction affected, Dm is
the median-effect dose (IC50 or ID50)t h a ti n h i b i t st h e
system under study by 50% and m is the coefficient sig-
nifying the sigmoidicity of the dose-effect relationship
[37]. The CI values obtained from the classic (mutually
exclusive) isobologram calculations were used. CI < 1.0,
CI = 1.0 and CI > 1.0 indicate synergism, additivity or
antagonism, respectively. Moderate synergism is
depicted by CI values between 0.7 and 0.9, synergism by
CI values below 0.7.
Results
Cytotoxicity of pemetrexed alone
A clear concentration-dependent cytotoxic effect of
pemetrexed was observed in CAL-27 and A549 cells,
with IC50 values of 118.77 ± 17.28 nM and 629.89 ±
68.77 nM respectively. The cytotoxicity of pemetrexed
was greatly dependent on the cell line used, as for
example in the PANC-1 pancreatic cell line, no dose-
response relationship was observed and concentrations
up to 1500 μM induced only 30% cell kill.
Combining pemetrexed with radiation
To investigate potential interactions between peme-
trexed and radiation therapy, CAL-27 and A549 tumour
cells were exposed to various doses of pemetrexed for
24 h (0-100 nM for CAL-27; 0-500 nM for A549),
immediately followed by irradiation (0-8 Gy) (table 1).
No concentration-dependent radiosensitising effect of
MTA was observed in CAL-27 cells, with DEF values
around 1.00 for all concentrations tested. CI analysis
showed that 24 h incubation with MTA immediately
before irradiation resulted in moderate antagonism
(1.1<CI<1.3). In the A549 cell line, DEFs slightly
decreased with an increasing concentration of MTA.
The mean CI varied from 0.689 ± 0.079 to 0.887 ±
0.294, indicating synergism to additivity.
Irradiation preceding 24 h incubation with MTA
resulted in an additive effect in CAL-27 cells, with DEFs
ranging from 0.87 ± 0.06 to 1.00 ± 0.24 and mean CI
values of 1.005 ± 0.080 to 1.039 ± 0.098. In A549 cells,
DEFs indicated a slightly radioprotective effect for this
treatment schedule (0.7<DEF<0.9). A closer look at the
CI analysis (figure 1A) showed that the interaction was
synergistic to moderately synergistic in the lower dose
range and shifted towards antagonism with increasing
doses of irradiation. This is also reflected in the dose-
survival curves.
To examine the role of a time interval between peme-
trexed and radiation treatment, CAL-27 and A549 cells
were incubated with only slightly cytotoxic concentra-
tions of MTA (i.e. 50 nM and 100 nM for resp. CAL-27
and A549) (figure 1B, C). Statistical analysis by two-way
ANOVA showed that the DEF was significantly influ-
enced by the time interval between MTA treatment and
irradiation in both CAL-27 (p = 0.005) and A549 (p =
0.014) cells. A 1 h time interval between 24 h MTA and
irradiation resulted in a clear radiosensitising effect in
both cell lines, with DEF 1.52 ± 0.39 for A549 cells and
1.46 ± 0.21 for CAL-27 cells (which was significantly
higher than the DEF for 24 h MTA immediately fol-
lowed by RT, p = 0.008). In the CAL-27 cell line, radio-
sensitisation was also observed after a 24 h or 8 h time
interval (DEF resp. 1.59 ± 0.53 and 1.23 ± 0.31), with CI
analysis indicating moderate synergism at the 8 h time
interval. In A549 cells, CI values increased from 0.677 ±
0.076 for the 1 h interval (synergism) to 0.832 ± 0.067
for the 24 h interval (moderate synergism). Concomi-
tantly, DEF values gradually decreased with an increas-
ing time interval between incubation with MTA and
irradiation.
Cell cycle distribution
Table 2 summarises the cell cycle distribution of CAL-
27 and A549 cells after incubation with pemetrexed for
2 4h ,f o l l o w e db yad r u gf r e ep e r i o do f0 ,1 ,4 ,8o r2 4
h. Treatment with pemetrexed for 24 h induced a signif-
icant increase in the percentage of S phase cells (control:
37.1 ± 1.3%; 24+0: 66.5 ± 6.2% in A549 cells), accompa-
n i e db yas i g n i f i c a n td e c r e a s ei nt h en u m b e ro fG 0/1
phase cells (control: 49.5 ± 3.1%; 24+0: 23.3 ± 6.1% in
A549 cells). These changes in cell cycle distribution
were observed for up to 8 h after drug removal, whereas
drug wash out for 24 h almost restored the normal dis-
tribution (figure 2). Statistical analysis using two-way
ANOVA revealed that the number of S phase cells was
significantly influenced depending on the cell line
(CAL-27 vs. A549), duration of drug wash out and con-
centration of pemetrexed (control vs. treated). Post hoc
analysis revealed a significant difference in the percen-
tage of S phase cells between the 24+24 schedule versus
the 24+1, 24+4 and 24+8 schedules.
Combining pemetrexed with gemcitabine
Considering the lack of concordance among previous
preclinical studies on pemetrexed-gemcitabine combina-
tions with regard to the preferable sequence of
drug administration, we first investigated different
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with irradiation.
The interaction between pemetrexed and gemcitabine
was investigated using three different schemes (cfr.
Methods). Simultaneous exposure to 24 h MTA and
24 h dFdC resulted in a significantly higher IC50 value
in both CAL-27 and A549 cells (e.g. for A549 IC50 for
24 h dFdC: 3.64 ± 0.27 nM; IC50 for 24 h dFdC + 24 h
200 nM MTA: 7.48 ± 1.48 nM) (table 3). The sequential
exposure of cell lines to 24 h pemetrexed followed by
24 h gemcitabine caused an increase in the IC50 values
too, which was significant for CAL-27 cells (e.g. IC50 for
24 h MTA: 119 ± 16 nM; IC50 for 24 h MTA ® 24 h 2
nM dFdC: 146 ± 12 nM). In contrast, the inverted
sequence induced a decrease in the IC50 value of MTA
in CAL-27 cells (IC50 for 24 h wash out ® 24 h MTA:
198 ± 15 nM; IC50 f o r2 4h2n Md F d C® 24 h MTA:
132 ± 15 nM). However, in A549 cells, 24 h gemcitabine
followed by 24 h pemetrexed induced an increase in
IC50 values in comparison with monotherapy with gem-
citabine or pemetrexed alone. Calculation of the combi-
nation index (figure 3A, B, D, E) showed antagonistic
interactions at the higher cytotoxic range. At fraction
effects between 0.25 and 0.75, all schedules (simulta-
neous and sequential) of 24 h gemcitabine and 24 h
MTA demonstrated synergistic to additive effects in
both CAL-27 and A549; however, though the differences
were not marked, the sequence 24 h dFdC ® 24 h
MTA seemed to be the most effective treatment
schedule.
The dose-effect curves of sequential combination of 1
h dFdC and 24 h MTA (figure 4) show that pemetrexed
enhanced the growth inhibition of 1 h gemcitabine in
both cell lines. Calculation of the CI value at fraction
effects between 0.25 and 0.75 (figure 3C, F) revealed
synergism in A549 cells, yet additivity in the CAL-27
Table 1 DEF, CI, ID50,S F 2 and % survival (representing the cytotoxic effect of treatment with MTA alone, 0 Gy) for
irradiation (RT) given alone or in combination with MTA using different treatment schedules: 24 h MTA immediately
followed by RT; RT immediately followed by 24 h MTA; 24 h MTA followed by different time intervals (24, 8, 4, 1, 0 h)
and subsequent irradiation
Condition DEF CI ID50 SF2 % survival
mean SD mean SD mean SD mean SD mean SD
CAL-27 RT 1.94 0.47 48.37 9.31 100% 0%
24 h 50 nM MTA ® RT 1.04 0.23 1.145 0.132 1.97 0.45 49.25 9.71 97% 11%
24 h 75 nM MTA ® RT 1.01 0.10 1.260 0.270 1.94 0.54 47.75 7.53 70% 12%
24 h 100 nM MTA ® RT 1.04 0.03 1.229 0.269 1.86 0.27 47.34 4.31 57% 4%
RT ® 24 h 50 nM MTA 0.87 0.06 1.039 0.098 1.86 0.46 46.21 9.19 88% 4%
RT ® 24 h 75 nM MTA 0.94 0.14 1.023 0.063 1.77 0.63 44.56 12.48 71% 8%
RT ® 24 h 100 nM MTA 1.00 0.24 1.005 0.080 1.65 0.41 42.40 10.00 59% 12%
24 h 50 nM MTA ® 24 h ® RT 1.59 0.53 † 0.915 0.063 1.71 0.66 43.37 12.35 70% 21%
24 h 50 nM MTA ® 8h® RT 1.23 0.31 0.844 0.091 * 1.55 0.58 39.45 12.88 88% 4%
24 h 50 nM MTA ® 4h® RT 1.12 0.24 0.965 0.106 1.68 0.58 42.34 12.02 90% 6%
24 h 50 nM MTA ® 1h® RT 1.46 0.21 † 0.932 0.073 1.21 0.35 † 32.45 8.43 † 98% 4%
A549 RT 2.41 0.39 56.26 6.18 100% 0%
24 h 100 nM MTA ® RT 1.29 0.25 0.698 0.079 ** 1.77 0.36 45.39 7.15 87% 11%
24 h 200 nM MTA ® RT 1.19 0.06 0.855 0.197 * 2.18 0.34 52.16 4.46 65% 12%
24 h 300 nM MTA ® RT 0.97 0.23 0.887 0.294 * 2.84 1.03 57.46 8.70 52% 14%
24 h 500 nM MTA ® RT 0.75 0.28 0.793 0.288 * 3.83 1.56 62.76 10.23 38% 13%
RT ® 24 h 200 nM MTA 0.86 0.19 0.996 0.124 2.77 0.20 60.24 3.01 68% 19%
RT ® 24 h 300 nM MTA 0.80 0.10 0.862 0.173 * 2.98 0.30 61.48 2.65 52% 16%
RT ® 24 h 500 nM MTA 0.76 0.11 0.723 0.166 * 3.11 0.19 62.75 1.09 38% 15%
24 h 100 nM MTA ® 24 h ® RT 0.98 0.15 0.832 0.067 * 2.16 0.11 52.70 2.00 84% 16%
24 h 100 nM MTA ® 8h® RT 1.21 0.18 0.731 0.129 * 2.02 0.24 50.62 4.87 85% 9%
24 h 100 nM MTA ® 4h® RT 1.56 0.41 0.718 0.103 * 1.63 0.35 42.19 6.30 94% 10%
24 h 100 nM MTA ® 1h® RT 1.52 0.39 0.677 0.076 ** 1.85 0.51 46.28 9.78 85% 11%
†: p < 0.05 vs. 24 h incubation with the same concentration of MTA immediately followed by RT; *: moderate synergism (0.7<CI<0.9); **: synergism (CI<0.7).
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MTA ® 1 h dFdC) induced a synergistic interaction in
both cell lines, with a significant decrease in IC50 values
(table 3). For example, sequential exposure to 200 nM
MTA followed by 1 h gemcitabine considerably reduced
the IC50 of 1 h gemcitabine from 569 ± 97 nM to 215 ±
22 nM. Taking into account IC50 values calculated from
t h es u r v i v a lc u r v e sa sw e l la st h eC Ia n a l y s i sf o rb o t h
CAL-27 and A549 cells, the degree of synergism
obtained with the 24 h MTA ® 1 h dFdC sequence was
remarkably greater than that observed with the other
schedules investigated.
Combining pemetrexed with gemcitabine and irradiation
CAL-27 and A549 cells were irradiated in combination
with different schedules of pemetrexed and gemcitabine
pretreatment. For all schedules included, treatment of
the tumour cells with gemcitabine, pemetrexed and
radiation produced growth inhibition that was additive
to synergistic in comparison to monotherapy with gem-
citabine, pemetrexed or irradiation alone (table 4). For
example, simultaneous administration of MTA and
dFdC for 24 h prior to irradiation resulted in CAL-27
and A549 cells in a dose enhancement factor of resp.
1.53 ± 0.27 and 1.49 ± 0.28. Both sequential schedules
with 1 h dFdC preceding or following 24 h MTA
showed radiosensitising potential (DEF 1.29-1.56), with
CI values indicating moderate synergism in CAL-27
cells and synergism in A549 cells. Especially 24 h MTA
followed by 1 h dFdC and irradiation seemed interesting
to us, since this scheme resulted in DEFs around 1.50 in
both cell lines. Moreover, the percentage of growth inhi-
bition induced by this drug combination (survival rate
65 ± 11% for CAL-27; 49 ± 8% for A549) was signifi-
cantly lower than the cytotoxic effect of MTA alone and
that of dFdC alone. This can be explained by the
Figure 1 MTA combined with irradiation. (A) Combination index
(CI) plots of radiation (RT) immediately followed by 24 h incubation
with various concentrations of MTA in A549 cells. The plots
represent the mean of at least three independent experiments. (B-C)
Radiation dose-response curves of CAL-27 (B) and A549 (C) cells
treated with 24 h MTA followed by different time intervals (24, 8, 4,
1, 0 h) and subsequent irradiation. Survival values from combination
experiments were normalised to MTA cytotoxicity (see table 1 for
the cytotoxic effect of MTA alone). Data points represent mean
values from at least three independent experiments; bars, SD.
Table 2 Influence of 24 h MTA on the percentage cells in
G1, S and G2/M phase
Condition G1 phase S phase G2/M phase
Mean SD mean SD mean SD
CAL-
27
24 h 0 nM MTA 49.3 2.2 34.3 2.5 10.8 2.4
24 h 50 nM MTA
® 0h
30.4 13.7 56.2 14.1 8.9 3.8
24 h 50 nM MTA
® 1h
30.9 12.9 54.5 12.3 * 9.5 4.0
24 h 50 nM MTA
® 4h
30.1 9.8 * 53.5 7.5 * 10.8 1.6
24 h 50 nM MTA
® 8h
29.0 0.1 * 49.1 2.4 * 15.2 2.0
24 h 50 nM MTA
® 24 h
41.5 7.9 38.9 6.8 9.2 8.1
A549 24 h 0 nM MTA 49.5 3.1 37.1 1.3 11.3 0.8
24 h 100 nM
MTA ® 0h
23.3 6.1 * 66.5 6.2 * 7.2 1.5 *
24 h 100 nM
MTA ® 1h
25.4 4.2 * 65.8 4.6 * 5.4 1.1 *
24 h 100 nM
MTA ® 4h
23.1 5.5 * 68.0 6.3 * 7.9 2.9
24 h 100 nM
MTA ® 8h
16.4 0.4 * 71.3 1.5 * 8.5 2.1
24 h 100 nM
MTA ® 24 h
57.1 18.8 38.2 0.8 12.4 0.9
Cell cycle analysis was performed 0, 1, 4, 8 or 24 h after drug wash out. *: p <
0.05 vs. untreated control
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Page 6 of 14synergistic interaction observed with the 24 h MTA ® 1
h dFdC combination (without radiotherapy).
Discussion
Today, the mainstay of cancer treatments consists of
surgery, radiotherapy and/or chemotherapy. In daily
practice, the combination of radiotherapy and che-
motherapy has become a standard treatment and it is
associated with improved survival rates in many
tumours, thereby favouring multimodal strategies in
tumour therapy. A multitude of potential interaction
mechanisms between radiotherapy and chemotherapy,
including radiosensitisation of tumour cells through
drug exposure, may improve treatment results [38].
Given the reported radiosensitising potential of both
gemcitabine [39] and pemetrexed [23], this paper, for
the first time, describes a preclinical study evaluating
the triple combination of pemetrexed, gemcitabine and
irradiation.
Concentration-dependent growth inhibition by single
agent treatment with gemcitabine or pemetrexed was
observed in both A549 lung carcinoma and CAL-27
head and neck carcinoma cell lines, with IC50 values
<1.0 μM in all cases, which is well below the mean peak
plasma concentration of both drugs achievable in
patients [40,41].
The interaction between pemetrexed and irradiation
was examined as a potential strategy to enhance the
therapeutic ratio of combined-modality cancer treat-
ment. However, incubation of CAL-27 or A549 cells
with 24 h pemetrexed immediately preceding or follow-
ing irradiation (0-8 Gy) was unable to produce any sig-
nificant radiosensitisation of the tumour cells. In
contrast, Bischof et al demonstrated that a concomitant
exposure to ionising radiation and moderately toxic con-
centrations of pemetrexed (106 nM, 70% survival) inhib-
ited clonogenic survival in excess of independent
toxicities in all four human tumour carcinoma cell lines
Figure 2 Influence of MTA on cell cycle distribution. DNA histograms of A549 cells at different time points after 24 h incubation with 100
nM MTA.
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Page 7 of 14tested, with enhancement ratios ranging from 1.2 (HeLa
cervix carcinoma and MCF-7 breast carcinoma cells) to
1.6 (LXI lung carcinoma cells). In WiDr colon
carcinoma cells, significant radiosensitisation (DEF 1.8)
was only noticed at higher pemetrexed concentrations
(636 nM, 85% survival), with a DEF of 1.1 when cells
were pretreated with 106 nM pemetrexed (no cytotoxic
effect) [23].
As the timing of irradiation relative to drug applica-
tion may play an important role in combined modality
treatments, tumour cells were irradiated at different
time intervals between 24 h pemetrexed treatment and
irradiation. Overall, including a time interval between
pemetrexed exposure and irradiation seemed favourable
to pemetrexed immediately preceding or following
radiotherapy, with DEFs up to 1.6 for CAL-27 cells. No
readily observable tendency in cell killing was shown
over the different time intervals. For both CAL-27 and
A549 cells, a 1 h time interval resulted in a clear radio-
sensitising effect (DEF 1.5). Similarly, no substantial var-
iation in survival fraction could be observed in WiDr
colon carcinoma cells when the interval between the
Table 3 IC50 and combination index (CI) values for MTA - dFdC combinations in CAL-27 and A549 cells
Condition CAL-27 A549
IC50 (nM) SD CI SD IC50 (nM) SD CI SD
24 h MTA ® 24 h wash out 118.53 16.37 569.47 120.60
24 h wash out ® 24 h MTA 198.25 14.51 1576.86 349.19
24 h MTA + 24 h 2 nM dFdC ® 24 h wash out 147.44 18.68 1.038 0.378 1689.43 1289.82 1.003 0.352
24 h MTA + 24 h 4 nM dFdC ® 24 h wash out 240.31 49.10 † 0.957 0.510 9120.46 1499.06 † 0.569 0.271 **
24 h MTA ® 24 h 2 nM dFdC 146.31 12.08 † 0.943 0.403 452.53 177.35 0.632 0.213 **
24 h MTA ® 24 h 4 nM dFdC 130.60 29.92 0.858 0.461 * 1069.95 1035.22 0.373 0.190 **
24 h 2 nM dFdC ® 24 h MTA 132.00 14.59 † 0.779 0.341 * 1322.54 833.14 0.546 0.237 **
24 h 4 nM dFdC ® 24 h MTA 172.68 42.09 0.739 0.373 * 6076.56 3648.50 0.384 0.154 **
24 h dFdC ® 24 h wash out 4.35 0.39 3.64 0.27
24 h wash out ® 24 h dFdC 5.87 0.17 5.30 0.20
24 h dFdC + 24 h 50 nM MTA ® 24 h wash out 4.25 0.37 1.141 0.858
24 h dFdC + 24 h 100 nM MTA ® 24 h wash out 5.82 0.68 † 1.201 0.843
24 h dFdC + 24 h 200 nM MTA ® 24 h wash out 7.48 1.04 † 1.112 0.972
24 h dFdC + 24 h 500 nM MTA ® 24 h wash out 19.40 11.06 1.167 0.967
24 h dFdC ® 24 h 50 nM MTA 3.83 0.07 1.073 0.872
24 h dFdC ® 24 h 100 nM MTA 3.61 0.20 1.179 1.071
24 h dFdC ® 24 h 200 nM MTA 4.90 1.79 0.873 0.924 *
24 h dFdC ® 24 h 500 nM MTA 7.08 1.87 0.921 0.942
24 h 50 nM MTA ® 24 h dFdC 4.88 0.29 † 0.961 0.591
24 h 100 nM MTA ® 24 h dFdC 5.89 0.83 1.158 0.870
24 h 200 nM MTA ® 24 h dFdC 6.96 2.52 0.830 0.848 *
24 h 500 nM MTA ® 24 h dFdC 14.81 10.54 0.838 0.806 *
1 h dFdC ® 24 h wash out 478.76 149.90 533.46 197.64
24 h wash out ® 1 h dFdC 495.55 130.97 569.36 96.66
1 h dFdC ® 24 h 50 nM MTA 571.61 262.49 1.154 0.349
1 h dFdC ® 24 h 100 nM MTA 386.35 92.33 0.980 0.185
1 h dFdC ® 24 h 200 nM MTA 421.84 237.54 0.693 0.287 **
1 h dFdC ® 24 h 500 nM MTA 407.32 187.49 0.570 0.265 **
24 h 50 nM MTA ® 1 h dFdC 271.36 38.36 0.880 0.466 *
24 h 100 nM MTA ® 1 h dFdC 166.12 16.64 † 0.803 0.413 *
24 h 200 nM MTA ® 1 h dFdC 215.44 21.72 † 0.880 0.682 *
24 h 500 nM MTA ® 1 h dFdC 217.14 24.80 † 0.681 0.494 **
†: p < 0.05 vs. IC50 of the corresponding drug alone; *: moderate synergism (0.7<CI<0.9); **: synergism (CI<0.7).
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Page 8 of 14start of 2 h pemetrexed exposure and irradiation was
varied from -4 h to +10 h [23]. This finding led to the
hypothesis that pemetrexed possibly exerts its radiosen-
sitising potential very rapidly and that this effect per-
tains after drug removal for an extended period of time
(at least 8 hours). Interestingly, a different behavior has
been reported for gemcitabine, where the radiosensitis-
ing potential gradually decreased with an increasing
time interval [34].
Our findings in CAL-27 and A549 cells, showing S
phase accumulation when cells were treated with only
slightly toxic concentrations of pemetrexed for 24 h, are
consistent with previous data in the A549 cell line
[22,42]. The S phase accumulation was observed for up
to 8 h after drug removal, yet disappeared after 24 h
wash out. This implies that the differences in radiosensi-
tisation could not be explained by the pemetrexed-
induced S phase accumulation (see also table 1 and 2).
Correspondingly, the study by Bischof et al also
excluded the S phase enrichment as the primary
mechanism for radiosensitisation by pemetrexed [23].
Moreover, tumour cell apoptosis was not found to be
responsible for pemetrexed-induced radiosensitisation in
human colon carcinoma cells [43]. Thus, the differential
radiosensitisation induced by pemetrexed cannot be
explained at present. A number of causes appear
Figure 3 Combination index (CI) plots of MTA - dFdC combinations in CAL-27 (A-C) and A549 (D-F) cells. Cells were treated with a
concentration range of MTA for 24 h (0-100 nM for CAL-27 cells; 0-2000 nM for A549 cells) combined with a constant concentration of dFdC for
24 h (2 or 4 nM) (A, D). Alternatively, cells were incubated with a concentration range of dFdC (0-100 nM for 24 h (B, E) or 0-5 μM for 1 h (C, F))
combined with a constant concentration of MTA (50 or 100 nM for CAL-27; 200 or 500 nM for A549). The plots represent the mean of at least
three independent experiments.
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Page 9 of 14conceivable (such as differences in drug toxicity levels,
growth characteristics of the cell lines investigated,
levels of drug-inhibited enzymes, or intracellular peme-
trexed polyglutamation), and further assessment of the
molecular mechanisms underlying the radiosensitising
potential of pemetrexed seems crucial.
Our study aimed at investigating the triple combina-
tion of gemcitabine, pemetrexed and irradiation. How-
ever, a recommended protocol for gemcitabine/
pemetrexed combinations differed among previously
published in vitro studies and there was generally no
agreement with regard to the preferable treatment sche-
dule. The drug combination has been examined in vitro
with different human tumour cell lines (including colon,
bladder and pancreatic cancer, NSCLC, and malignant
pleural mesothelioma), resulting in controversial sche-
dule-dependent interactions. Though simultaneous drug
administration is the more frequently used and most
practical clinical regimen, results from the present and
previous in vitro studies showed that simultaneous
exposure to these two antimetabolites did not signifi-
cantly increase cell kill and thus probably will not
improve the clinical therapeutic effect [42,44,45]. Con-
versely, we observed that sequential exposure produced
a greater cytotoxic effect than that exerted by single-
agent use or simultaneous exposure. In particular, as
shown by the IC50 values calculated from survival curves
as well as the results from CI analysis in both A549 and
CAL-27 cells, a higher synergistic interaction was
obtained by pretreatment with 24 h pemetrexed fol-
lowed by 1 h gemcitabine (24 h MTA ® 1 h dFdC) in
comparison with the other schedules investigated. These
findings are in agreement with previous reported obser-
vations in the A549 NSCLC cell line by Giovannetti et
al [22,30]; for the CAL-27 SCCHN cell line, no previous
data are available. In the clinic, a phase I trial in patients
with advanced solid tumours suggested that the
sequence of gemcitabine administered on days 1 and 8
with pemetrexed administered on day 8, 90 minutes
after gemcitabine was well tolerated and recommended
for further study [46]. However, a few years later, the
same research group conducted a phase II trial of three
schedules of pemetrexed and gemcitabine as front-line
therapy for advanced NSCLC. In this trial, the peme-
trexed-gemcitabine schedule was less toxic compared
with other sequences and, by obtaining a confirmed
response rate of 31%, was the only schedule that met
the protocol-defined efficacy criteria [47]. As such, both
preclinical and clinical data support the sequential
pemetrexed-gemcitabine schedule in NSCLC.
Figure 4 Inhibitory effect of 24 h MTA - 1 h dFdC combinations on cell survival of CAL-27 (A, B) and A549 (C, D) tumour cells. Survival
curves were corrected for the cytotoxic effect of 24 h MTA alone. In CAL-27, 24 h incubation with 50 or 100 nM MTA resulted in resp. 90 ± 7%
and 73 ± 8% survival. In A549, 24 h incubation with 200 or 500 nM MTA resulted in resp. 73 ± 10% and 50 ± 7% survival. Data points represent
mean values from at least three independent experiments; bars, SD.
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Page 10 of 14Concerning the molecular basis for pemetrexed-gem-
citabine interactions, it has been suggested that the
favourable modulation of the cell cycle by pemetrexed
m a yb ec o n s i d e r e da so n eo ft h em o s ti m p o r t a n t
mechanisms underlying the synergistic interaction in the
24 h MTA ® 1 h dFdC sequence [22]. Because gemcita-
bine is an S phase specific drug, the increase in its activ-
ity in this schedule may be the result of the S phase
accumulation induced by pemetrexed, which potentially
facilitates incorporation of 2′,2′-difluoro-deoxycytidine
triphosphate into the DNA. As the cell cycle modulation
by pemetrexed lasted for several hours after drug
removal, but disappeared after 24 h, this may explain
why the 24 h MTA ® 1 h dFdC seems preferable to the
24 h MTA ® 24 h dFdC schedule.
In A549 cells, it has been demonstrated that peme-
trexed, at its IC50 and IC75 levels, significantly upregu-
lated the hENT1 carrier, potentially facilitating
gemcitabine cytotoxicity [22]. Moreover, being an inhibi-
t o ro fd en o v op u r i n eb i o s y nthesis (because of the
blockade of the key enzyme GARFT), pemetrexed was
shown to increase the expression of dCK as a compen-
satory mechanism [22]. The dCK activity of untreated
A549 and CAL-27 cells was reported to be highly com-
parable (resp. 6.02 and 5.02 nmol/h/mg protein) and a
weak positive correlation between dCK activity and the
radiosensitising effect of gemcitabine has been reported
[48], suggesting that enhancement of hENT1 and dCK
expression by pemetrexed in the pemetrexed ® gemci-
tabine sequence strongly supports this combination.
Table 4 DEF, CI, ID50,S F 2 and % survival (representing the cytotoxic effect of treatment with MTA and/or dFdC alone,
0 Gy) for MTA - dFdC - irradiation (RT) combinations in CAL-27 and A549 cells
Condition DEF CI ID50 SF2 % survival
mean SD mean SD mean SD mean SD mean SD
CAL-27 RT 1.94 0.47 48.37 9.31 100% 0%
24 h 50 nM MTA ® RT 1.04 0.23 1.095 0.127 1.97 0.45 49.25 9.71 97% 11%
24 h 50 nM MTA ® 24 h ® RT 1.59 0.53 0.916 0.063 1.71 0.66 43.37 12.35 70% 21%
24 h 50 nM MTA ® 1h® RT 1.46 0.21 0.933 0.073 1.21 0.35 32.45 8.43 98% 4%
24 h 2 nM dFdC ® RT 1.47 0.09 0.888 0.180 * 1.72 0.10 49.25 9.71 96% 1%
24 h 2 nM dFdC ® 24 h ® RT 1.04 0.16 1.090 0.101 2.43 0.08 58.31 2.96 84% 18%
1 h 100 nM dFdC ® 24 h ® RT 1.56 0.46 0.653 0.108 ** 1.32 0.25 34.09 5.34 91% 24%
1 h 50 nM dFdC ® RT 1.07 0.19 0.917 0.124 1.69 0.64 44.73 14.77 98% 14%
24 h 2 nM dFdC + 24 h 50 nM MTA ® RT 1.53 0.27 † 0.960 0.267 1.66 0.09 42.27 1.03 98% 11%
24 h 2 nM dFdC ® 24 h 50 nM MTA ® RT 1.38 0.09 0.949 0.106 1.85 0.34 46.93 6.81 75% 4% †
24 h 50 nM MTA ® 24 h 2 nM dFdC ® RT 1.78 0.14 0.705 0.097 * 1.42 0.06 36.83 3.36 64% 22%
1 h 100 nM dFdC ® 24 h 50 nM MTA ® RT 1.56 0.37 † 0.801 0.094 * 1.29 0.20 † 34.65 4.07 † 71% 15% †
24 h 50 nM MTA ® 1 h 50 nM dFdC ® RT 1.43 0.57 0.858 0.175 * 1.30 0.45 34.93 10.25 65% 11% †;††
A549 RT 2.41 0.39 56.26 6.18 100% 0%
24 h 100 nM MTA ® RT 1.29 0.25 0.674 0.053 ** 1.77 0.36 45.39 7.15 87% 11%
24 h 100 nM MTA ® 24 h ® RT 0.98 0.15 0.838 0.070 * 2.16 0.11 52.70 2.00 84% 16%
24 h 100 nM MTA ® 1h® RT 1.52 0.39 0.681 0.084 ** 1.85 0.51 46.28 9.78 85% 11%
24 h 2 nM dFdC ® RT 1.55 0.24 0.538 0.057 ** 1.25 0.08 34.55 2.01 71% 16%
24 h 2 nM dFdC ® 24 h ® RT 0.99 0.31 0.703 0.118 * 2.04 0.40 50.19 6.96 65% 4%
1 h 100 nM dFdC ® 24 h ® RT 1.23 0.23 0.606 0.073 ** 1.97 0.24 49.28 4.36 67% 13%
1 h 50 nM dFdC ® RT 1.49 0.39 0.831 0.068 * 1.92 0.49 47.99 8.72 96% 5%
24 h 2 nM dFdC + 24 h 100 nM MTA ® RT 1.49 0.28 0.564 0.075 ** 1.32 0.30 36.11 6.47 66% 23%
24 h 2 nM dFdC ® 24 h 100 nM MTA ® RT 0.94 0.27 0.585 0.101 ** 2.21 0.80 52.39 11.98 47% 14%
24 h 100 nM MTA ® 24 h 2 nM dFdC ® RT 1.17 0.24 0.500 0.073 ** 1.69 0.36 44.34 7.16 48% 16% †
1 h 100 nM dFdC ® 24 h 100 nM MTA ® RT 1.29 0.27 0.513 0.053 ** 1.88 0.25 47.68 4.45 48% 12% †
24 h 100 nM MTA ® 1 h 50 nM dFdC ® RT 1.52 0.58 0.534 0.083 ** 1.92 0.50 47.93 9.71 49% 8% †;††
†: p < 0.05 vs. corresponding schedule of MTA and RT; ††: p < 0.05 vs. corresponding schedule of dFdC and RT; *: moderate synergism (0.7<CI<0.9); **:
synergism (CI<0.7).
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Page 11 of 14In addition, several studies showed that TS expression
is significantly correlated with pemetrexed sensitivity
both in a preclinical and clinical setting [22,49]. Func-
tional inactivity and mutations of p53 were shown to
differentially affect the expression and activity of TS
[50], potentially influencing the response of A549 (wt
p53) and CAL-27 (mt p53) cells to pemetrexed-based
treatment. Nevertheless, different conclusions regarding
the relationship between functional p53 status and sen-
sitivity to pemetrexed have been obtained, possibly
depending on the phenotypic/genotypic background of
the model system used [29,51-53]. Similarly, the role of
p53 on the ability of gemcitabine to induce a cytotoxic
and radiosensitising effect is not yet completely eluci-
dated [6,54,55], making further mechanistic unravelling
of the pemetrexed-gemcitabine-radiation combination
highly warranted.
When combining pemetrexed and gemcitabine with
irradiation, the 24 h MTA ® 1hd F d C® RT regimen
showed radiosensitising potential in both cell lines (DEF
1.4 for CAL-27; 1.5 for A549). Other pemetrexed/gemci-
tabine schedules in combination with radiation also pro-
duced additive to synergistic growth inhibition in
comparison to monotherapy, and the corresponding
DEFs were not significantly different from these obtained
with 24 h MTA ® 1 h dFdC ® RT. However, given the
synergistic interaction between 24 h pemetrexed and 1 h
gemcitabine, the 24 h MTA ® 1hd F d C® RT turned
out to be the preferred schedule for combined adminis-
tration with radiotherapy in our preclinical model system.
Conclusions
This study characterises, for the first time, the interac-
tions between gemcitabine, pemetrexed and radiotherapy.
Preliminary results from our in vitro model suggest that
the sequence 24 h MTA ® 1 h dFdC ® RT is the most
rational design. Further in depth mechanistic unravelling
of the pemetrexed-gemcitabine-radiation combination is
certainly needed. As extrapolation of in vitro data to the
clinic should be considered with caution, the experiments
provide a strong experimental basis for future develop-
ment of this triple combination in an in vivo setting.
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